Phase I trial of trimetrexate in pediatric solid tumors: a Pediatric Oncology Group study.

Abstract

Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily x 5 every three weeks. Starting dose was 6.4 mg/m2/day. Dose was escalated by 20% until the maximal tolerated dose was reached. A total of 75 courses were administered to 26 children. The major toxicity was myelosuppression, of which neutropenia and thrombocytopenia were most prominent. Rash, mucositis, and transient liver enzyme elevations were infrequently seen. Responses were observed in children with brainstem glioma, neuroblastoma, and renal cell carcinoma. The recommended Phase II dose using this schedule is 9.2-11 mg/m2/day depending on how heavily the patient has been treated prior to initiating this therapy.

• Authors: A S Pappo, T Vats, T E Williams, M Bernstein, B A Kamen
• Journal: Medical and pediatric oncology (Med Pediatr Oncol) Vol. 21 Issue 4 Pg. 280-2 ( 1993) ISSN: 0098-1532 [Print] United States
• PMID: 8469224 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Trimetrexate

Topics

• Adolescent
• Adult
• Brain Neoplasms (drug therapy)
• Carcinoma, Renal Cell (drug therapy)
• Child
• Child, Preschool
• Female
• Follow-Up Studies
• Glioma (drug therapy)
• Humans
• Infant
• Infusions, Intravenous
• Leukopenia (chemically induced)
• Male
• Neoplasms (drug therapy)
• Neuroblastoma (drug therapy)
• Thrombocytopenia (chemically induced)
• Trimetrexate (administration & dosage, adverse effects, therapeutic use)